 BeyondSpring Pharmaceuticals NASDAQ: BYSI announced new plinabulin data from its chemotherapy-induced neutropenia CIN prevention program at the European Society for Medical Oncology ESMO21 2021 Congress. Plinabulin combined with G-CSF to prevent CIN is currently under U.S. and China regulatory review with an FDA PDUFA date of November 30. 